Determination of Clinical Characteristics of Mycobacterium kansasii -Derived Species by Reanalysis of Isolates Formerly Reported as M. kansasii
0
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Background: Seven genotypic subtypes of Mycobacterium kansasii were recently demonstrated to represent distinct species based on phylogenomic analysis. Mycobacterium kansasii sensu stricto (formerly known as subtype 1) is most frequently associated with human diseases; only a few studies have compared the diverse clinical characteristics of M. kansasii subtypes, including their drug susceptibilities. We determined the actual incidence of infections caused by each subtype of M. kansasii and identified their clinical characteristics. Methods: We subtyped isolates identified as M. kansasii over the last 10 years at a tertiary care hospital. Percent identity score of stored sequencing data was calculated using curated reference sequences of all M. kansasii subtypes. Clinical characteristics were compared between those classified as subtype 1 and other subtypes. Student’s t-test, Wilcoxon rank-sum test, and Fisher’s exact test were used for comparisons. Results: Overall, 21.7% of the isolates were identified as species distinct from M. kansasii. The proportion of patients with subtype 1 M. kansasii infection who received treatment was significantly higher than that of patients with other subtype infections (55.3% vs. 7.7%, P=0.003). Only patients with subtype 1 infection received surgical treatment. Non-subtype 1 M. kansasii isolates showed a higher frequency of resistance to ciprofloxacin and trimethoprim/sulfamethoxazole. Conclusions: Non-subtype 1 M. kansasii isolates should be separately identified in routine clinical laboratory tests for appropriate treatment selection.
Abstract
Background: Seven genotypic subtypes of Mycobacterium kansasii were recently demonstrated to represent distinct species based on phylogenomic analysis. Mycobacterium kansasii sensu stricto (formerly known as subtype 1) is most frequently associated with human diseases; only a few studies have compared the diverse clinical characteristics of M. kansasii subtypes, including their drug susceptibilities. We determined the actual incidence of infections caused by each subtype of M. kansasii and identified their clinical characteristics. Methods: We subtyped isolates identified as M. kansasii over the last 10 years at a tertiary care hospital. Percent identity score of stored sequencing data was calculated using curated reference sequences of all M. kansasii subtypes. Clinical characteristics were compared between those classified as subtype 1 and other subtypes. Student’s t-test, Wilcoxon rank-sum test, and Fisher’s exact test were used for comparisons. Results: Overall, 21.7% of the isolates were identified as species distinct from M. kansasii. The proportion of patients with subtype 1 M. kansasii infection who received treatment was significantly higher than that of patients with other subtype infections (55.3% vs. 7.7%, P=0.003). Only patients with subtype 1 infection received surgical treatment. Non-subtype 1 M. kansasii isolates showed a higher frequency of resistance to ciprofloxacin and trimethoprim/sulfamethoxazole. Conclusions: Non-subtype 1 M. kansasii isolates should be separately identified in routine clinical laboratory tests for appropriate treatment selection.
참고문헌 (25)
- Koh WJ, "Clinical significance of nontuberculous mycobacteria isolated from respiratory specimens in Korea", Chest, 129, pp.341~348 (2006)
- Van Ingen J, "Clinical relevance of non-tuberculous mycobacteria isolated in the Nijmegen-Arnhem region, The Netherlands", Thorax, 64, pp.502~506 (2009)
- Matveychuk A, "Clinical and radiological features of Mycobacterium kansasii and other NTM infections", Respir Med, 106, pp.1472~1477 (2012)
- Jagielski T, "Genomic insights into the Mycobacterium kansasii complex: an update", Front Microbiol, 10, pp.2918~ (2020)
- Alcaide F, "Heterogeneity and clonality among isolates of Mycobacterium kansasii: implications for epidemiological and pathogenicity studies", J Clin Microbiol, 35, pp.1959~1964 (1997)
- Picardeau M, "Genotypic characterization of five subspecies of Mycobacterium kansasii", J Clin Microbiol, 35, pp.25~32 (1997)
- Taillard C, "Clinical implications of Mycobacterium kansasii species heterogeneity: Swiss National Survey", J Clin Microbiol, 41, pp.1240~1244 (2003)
- Kim BJ, "Differentiation of mycobacterial species by PCR-restriction analysis of DNA (342 base pairs) of the RNA polymerase gene (rpoB)", J Clin Microbiol, 39, pp.2102~2109 (2001)
- Bakuła Z, "Proposal of a new method for subtyping of kansasii based upon PCR restriction enzyme analysis of the tuf gene", Diagn Microbiol Infect Dis, 84, pp.318~321 (2016)
- Zhang Y, "Molecular analysis of Mycobacterium kansasii isolates from the United States", J Clin Microbiol, 42, pp.119~125 (2004)
- da Silva Telles MA, "Mycobacterium kansasii: antibiotic susceptibility and PCR-restriction analysis of clinical isolates", J Med Microbiol, 54, pp.975~979 (2005)
- Bakuła Z, "Drug susceptibility profiling and genetic determinants of drug resistance in Mycobacterium kansasii", Antimicrob Agents Chemother, 62, pp.e01788-17~ (2018)
- Guan Q, "Comparative genomic and transcriptomic analyses of Mycobacterium kansasii subtypes provide new insights into their pathogenicity and taxonomy", Front Cell Infect Microbiol, 10, pp.122~ (2020)
- Li Y, "Mycobacterium kansasii Subtype I is associated with clarithromycin resistance in China", Front Microbiol, 7, pp.2097~ (2016)
- Shahraki AH, "Mycobacterium persicum sp. nov., a novel species closely related to Mycobacterium kansasii and Mycobacterium gastri", Int J Syst Evol Microbiol, 67, pp.1766~1770 (2017)
- Tagini F, "Phylogenomics reveal that Mycobacterium kansasii subtypes are species-level lineages. Description of Mycobacterium pseudokansasii sp. nov., Mycobacterium innocens sp. nov. and Mycobacterium attenuatum sp. nov", Int J Syst Evol Microbiol, 69, pp.1696~1704 (2019)
- Parker CT, "International code of nomenclature of prokaryotes: prokaryotic code", Int J Syst Evol Microbiol, 69, pp.S1~S111 (2019)
- CLSI, "Laboratory detection and identification of mycobacteria" (2018), Clinical and Laboratory Standards Institute
- 박혜경, "Clinical Characteristics and Treatment Outcomes of Mycobacterium kansasii Lung Disease in Korea", Yonsei Medical Journal, 51(4), pp.552~556 (2010), 연세대학교의과대학
- Moon SM, "Clinical significance of Mycobacterium kansasii isolates from respiratory specimens", PLoS One, 10, pp.e0139621~ (2015)
- Bloch KC, "Incidence and clinical implications of isolation of Mycobacterium kansasii: results of a 5-year, population-based study", Ann Intern Med, 129, pp.698~704 (1998)
- Shitrit D, "Pulmonary Mycobacterium kansasii infection in Israel, 1999-2004: clinical features, drug susceptibility, and outcome", Chest, 129, pp.771~776 (2006)
- Bodle EE, "Epidemiology of nontuberculous mycobacteria in patients without HIV infection, New York City", Emerg Infect Dis, 14, pp.390~396 (2008)
- Simons S, "Nontuberculous mycobacteria in respiratory tract infections, Eastern Asia", Emerg Infect Dis, 17, pp.343~349 (2011)
- CLSI, "Susceptibility testing of mycobacteria, nocardiae, and other aerobic actinomycetes" (2011), Clinical and Laboratory Standards Institute